Live
Endpoints NewsBiopharma’s 2025 industry pay report; Parabilis sets industry record IPO; and moreClinical OMICsLong-Read DNA Test Could Replace 15 Existing Tests for Rare DiseasesClinical OMICsMaternal Blood Test Allows Comprehensive Genetic Fetal ScreeningEndpoints NewsMerck brings Welireg-Keytruda combo to treat kidney cancerFDA News ReleasesFDA Clears First Over-the-Counter Continuous Glucose Monitor for ChildrenClinical OMICsFrom Multi-Omics to Digital Twins: A Data-Driven Future for Precision MedicineClinical OMICsAge-Related Mutations in Brain Immune Cells Linked to Alzheimer’s InflammationClinical OMICsPaper Mills and the Fight Against Scientific FraudClinical OMICsNanowire Device Captures EVs for Targeted Cancer Liquid BiopsiesCellComplete biosynthesis of the anticancer cephalotaxinone and homoerythratineEndpoints NewsAmgen and the FDA want two different outcomes for Tavneos. What will patients do?Endpoints NewsEli Lilly invests in startup Abridge for clinical trial recruitment
FierceBiotech 5 janv. 2026

Insilico, fresh off its Hong Kong IPO, pens potential $888M cancer R&D pact with Servier

Insilico, fresh off its Hong Kong IPO, pens potential $888M cancer R&D pact with Servier

Original
Contenu indisponible. Consultez la source originale.